Step It Up: Branding Roundtable - Pharmaceutical Executive

ADVERTISEMENT

Step It Up: Branding Roundtable


Pharmaceutical Executive


GUARINI: But could it boomerang back on the companies? Will I resent that if I had been taking Zocor for the last 10 years, and it was $180 a month, that I am now paying $40?

WILKES: It depends if your relationship is with simvastatin or with Merck. If it's with Merck, the company has to tell the patient what is coming, and why there is a price disparity. Right now, that information comes from the pharmacist.

BOKEN: The biggest opportunity is with life-saving drugs. If I get a cancer treatment that literally brings me back to life, then I would be willing to continue to buy from the original manufacturer.

HUNTSMAN: If there is more pharmacovigilance, what will be required of generic companies? Will they have to take on the costs of expensive risk-management programs? That may be a barrier to entry for some generic companies.

BREITSTEIN: And certainly an opportunity. Thank you all for participating.


ADVERTISEMENT

blog comments powered by Disqus
UPCOMING CONFERENCES

Serialization Summit
San Diego, CA
Feb. 27-28, 2014



Advances in Aseptic Processing
San Diego, CA
Mar. 10-12, 2014



ClinTech 2014
Cambridge, MA
Mar. 11-13 2014


Investigator-Initiated and
Sponsored Research (IISR)

Philadelphia, PA
Mar. 19-20 2014

See All Conferences >>

Source: Pharmaceutical Executive,
Click here